Cell Therapeutics has filed a supplemental Biologics License Application for the use of Zevalin as consolidation therapy in follicular non-Hodgkin's lymphoma patients. If approved, the drug would be the only radioimmunotherapy in the U.S. cleared for first-line consolidation therapy, the company said. Zevalin is approved for use in patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma.

Full Story:
RTT News

Related Summaries